Author:
Dhippayom Teerapon,Boonpattharatthiti Kansak,Kategeaw Warittakorn,Hong Heeseung,Chaiyakunapruk Nathorn,Barnes Geoffery D.,Witt Daniel
Reference55 articles.
1. Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020;Lsd Costa;J Thromb Thrombolysis,2023
2. Oral anticoagulants around the world: an updated state-of-the art analysis;G Lippi;Ann Blood,2018
3. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study;N S Abraham;BMJ,2015
4. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care;Y Vinogradova;Bmj. Jul,2018
5. Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials;Y H Lee;Lupus,2022